Integrative analysis shows MMR genes predict outcomes in gastric cancer, indicating their prognostic relevance.
Background Mismatch repair (MMR) genes are implicated in stomach adenocarcinoma (STAD). This study assessed their causal role in STAD, prognostic value, and developed a histopathology‐based model to predict MutS homolog 2 (MSH2) expression. Methods Using data from the IEU OpenGWAS database, five Mendelian randomization (MR) models evaluated causal links between MMR genes and gastric cancer (GC). Prognostic relevance was assessed via survival analysis. A random forest model using TCGA hematoxylin and eosin–stained images was trained to predict MSH2 expression. Biological insights were explored via pathomics score, gene set enrichment analysis (GSEA), immune infiltration, and tumor mutational burden (TMB). Results MR analysis identified MLH1 and PMS2 as risk genes, while MSH2 had a protective effect. Cox regression confirmed MSH2 as an independent protective factor (HR = 0.690, 95% CI: 0.487–0.977, p < 0.05). The pathomics model predicted MSH2 expression with an AUC of 0.811. A comparison of high‐ and low‐survival‐probability (SP) groups showed differentially expressed genes, including SFRP4. The high‐SP group had elevated TMB and TP53 mutation frequency. Conclusion MMR genes, especially MSH2, are critical in STAD development and prognosis. The image‐based model effectively predicts MSH2 expression, supporting the integration of genomic and histopathologic data for personalized GC care.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: